BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Aragon Pharmaceuticals, Inc. Announces Key Strategic Hire


2/11/2013 9:25:19 AM

SAN DIEGO, CA--(Marketwire - February 11, 2013) - Aragon Pharmaceuticals Inc., a leader in developing drugs for hormone driven cancers, today announced that Paul Cleveland has joined the company as Chief Financial Officer and Executive Vice President, Corporate Strategy. In this role, Mr. Cleveland will be responsible for the company's finance, legal, investor relations and business development matters.

"We are pleased to welcome Paul to Aragon," said Richard A. Heyman, Ph.D., President and CEO of Aragon Pharmaceuticals. "His extensive experience across business development, legal, and finance in public and private companies will add tremendous value to the company. Paul joins Aragon at an optimal time, strengthening our management team and corporate development capabilities, as we continue to progress our pipeline, including ARN-509 into late stage clinical trials."

Prior to Aragon, Mr. Cleveland spent two years as a General Partner and Chief Operating Officer at Mohr Davidow Ventures. Previously, he spent five years at Affymax Inc., where he served as Executive Vice President, Corporate Development and Chief Financial Officer, leading the Company through its successful public offering in 2006. Prior to Affymax, Mr. Cleveland was a Managing Director at JP Morgan (formerly Hambrecht & Quist), where he served as Head of West Coast Mergers and Acquisitions. He also brings to Aragon 15 years of experience as a practicing attorney, most recently as a Partner within the Corporate Group at Cooley Godward in Palo Alto, CA. Mr. Cleveland has served as a member of the Board of Directors of three biotechnology companies, and currently serves as a member of the Board of Sangamo Biosciences, Inc.

"I am excited to be joining such a high quality team as the company transitions to its next stage of corporate growth," said Mr. Cleveland. "There is nothing more gratifying than helping to develop treatment options for cancer patients in need."

About Aragon Pharmaceuticals

Aragon Pharmaceuticals is focused on the development of 2nd generation anti-hormonal agents for hormone-driven cancers. The company's portfolio of small molecule therapeutics is based upon pioneering research identifying key molecular events that lead to drug resistance to traditional anti-hormonal therapies. This work has broad implications for the development of breakthrough medicines for prostate cancer and other hormone-dependent cancers such as breast, ovarian and endometrial cancer. Aragon Pharmaceutical's most advanced compound, ARN-509, is an androgen receptor antagonist that is currently being evaluated in a Phase 2 trial in patients with castration-resistant prostate cancer. In addition, Aragon Pharmaceuticals has a selective estrogen receptor degrader (SERD) for hormone-sensitive and hormone-resistant estrogen receptor positive breast cancer targeted to begin clinical trials in 2013. Aragon is a private company founded in 2009 and headquartered in San Diego, California. For more information, visit

www.aragonpharm.com


Contact:

Laura Forman
Blueprint Life Science Group
Email Contact
(415) 375-3340, ext 103



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->